COMMUNIQUÉS West-GlobeNewswire

Origin Successfully Achieves Phase IIb GENESIS Trial Objectives Ahead of Schedule and Announces Early Termination of Study

18/04/2018 - 14:30

PRINCETON, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Origin, Inc., a Phase IIb clinical-stage biotechnology company, today announced that the US Food and Drug Administration has approved its request to conclude patient [...]

Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology Meeting

18/04/2018 - 14:30

PROMISE 2 Phase 3 study selected for Emerging Science clinical trials plenary presentation session on April 24, 2018 BOTHELL, Wash., April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a [...]

Interpace Diagnostics Enters Agreement with One of the Largest, Integrated Health Systems in the US

18/04/2018 - 14:30

Agreement with BJC Healthcare Covers Both of the Company’s Thyroid Tests PARSIPPANY, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG ) (“Interpace” or “the Company”), a fully [...]

Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

18/04/2018 - 14:30

Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX ), a leader in the [...]

INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device

18/04/2018 - 14:30

PHOENIX, April 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced [...]

Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute

18/04/2018 - 14:05

- Beta-glucan project expected to be Ceapro’s first clinical project led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) - EDMONTON, ALBERTA, April 18, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO [...]

Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018

18/04/2018 - 14:00

NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’ [...]

Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia

18/04/2018 - 14:00

Protocol for Pivotal Clinical Trial Has Been Submitted to the US FDA LOS ALTOS, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today peer-reviewed publication of positive Phase 1b/2a trial results for [...]

Trayt Unveils Application to Improve Diagnosis, Treatment and Quality of Life for Patients with Autism, ADHD and Neurodevelopmental Disorders

18/04/2018 - 14:00

Big Data and Analytics Platform Measures Efficacy of Interventions and Engages the Entire System of Care REDWOOD CITY, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Trayt , the data analytics company with a platform for [...]

Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

18/04/2018 - 14:00

Grant Expected to Fund Development of OPNT003 to NDA Ready Stage SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT ), a specialty pharmaceutical company [...]

CareDx Closes Debt Refinancing

18/04/2018 - 14:00

$15 Million Term Loan with Perceptive Advisors BRISBANE, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ), a molecular diagnostics company focused on the discovery, development and [...]

Fibrocell Announces Review of Strategic Alternatives

18/04/2018 - 14:00

EXTON, Pa., April 18, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]

“I Would Choose SkinTE Every Time,” says Patient Treated with PolarityTE’s New Skin Regeneration Product

18/04/2018 - 14:00

SALT LAKE CITY, April 18, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (NASDAQ: COOL ) today announced continued success with SkinTE during its limited-market release across a variety of conditions, including burns, wounds [...]

83% of People with Alcohol Problems Are Never Encouraged to Seek Treatment

18/04/2018 - 13:48

VANCOUVER, B.C., April 18, 2018 (GLOBE NEWSWIRE) -- With April being Alcohol Awareness Month, studies show 83% of Canadians who drink excessively received no advice or encouragement from family and friends to cut down [...]

AzurRx BioPharma Announces Positive Preclinical Data with AZX1103

18/04/2018 - 13:45

Company is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of antibiotics AZX1103 shown to be safe and biologically active in a well-established pre-clinical [...]

Precipio in Strategic Partnership Discussions for Proprietary Cytogenetics Media IV-Cell

18/04/2018 - 13:38

NEW HAVEN, Conn., April 18, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO ), announced today it is in active licensing discussions with several potential partners regarding IV-Cell [...]

Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

18/04/2018 - 13:30

SAN DIEGO, April 18, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT ), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today [...]

Radient Technologies Inc. Finalizes Real Estate Transactions for Expansion and Provides Corporate Update

18/04/2018 - 13:30

EDMONTON, Alberta, April 18, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce the following update on its operations and 2018 growth initiatives. [...]

Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development

18/04/2018 - 13:30

- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and Johnson & [...]